Brinzolamide

Brinzolamide
Clinical data
Pronunciationbrin ZOH la mide
Trade namesAzopt
AHFS/Drugs.comMonograph
MedlinePlusa601233
License data
Pregnancy
category
Routes of
administration		Ophthalmic
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Pharmacokinetic data
BioavailabilityAbsorbed systemically, but below detectable levels (less than 10 ng/mL)
Protein binding~60%
Elimination half-life111 days
ExcretionKidney (60%)
Identifiers
  • (5R)-5-ethylamino-3-(3-methoxypropyl)-
    2,2-dioxo-2λ6,9-dithia-
    3-azabicyclo[4.3.0]nona-7,10-diene-
    8-sulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.149.376 Edit this at Wikidata
Chemical and physical data
FormulaC12H21N3O5S3
Molar mass383.50 g·mol−1
3D model (JSmol)
  • O=S(=O)(c1sc2c(c1)[C@@H](NCC)CN(CCCOC)S2(=O)=O)N
  • InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1 checkY
  • Key:HCRKCZRJWPKOAR-JTQLQIEISA-N checkY
  (verify)

Brinzolamide (trade name Azopt) is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Brinzolamide was approved as a generic medication in the United States in November 2020.[2]

  1. ^ "Brinzolamide ophthalmic (Azopt) Use During Pregnancy". Drugs.com. 16 May 2019. Retrieved 17 August 2020.
  2. ^ "First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). Retrieved 13 February 2021.